
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Workshop on AI in GMP Manufacturing: Shaping Future Guidance from EMA
The European Medicines Agency is convening a two-day multistakeholder workshop to collect expert contributions that will inform the development of Annex 22 guidance on AI in GMP Manufacturing. Date: 30 June – 1 July 2026
Format: Hybrid The event features:
...
Developer Engagement Misalignment: Challenges in Assessing Advanced Therapies
Advanced Therapy Medicinal Products (ATMPs) offer transformative options for rare and previously untreatable conditions, yet their high upfront costs, uncertain durability, and single-arm trial data create major reimbursement barriers. The 2026 pre-proof study by Greco et al. shows that developer...
MEA Adoption Challenges in Advanced Therapy Medicinal Products: Insights and Implications
MEA Adoption Challenges continue to limit the practical use of Managed Entry Agreements for Advanced Therapy Medicinal Products across Europe. The 2026 pre-proof paper by Greco et al. draws on interviews with HTA bodies and payers in England, the Netherlands, and Spain to show that hybrid agreeme...